Reported about 19 hours ago
CytomX Therapeutics, Inc. (CTMX) has released encouraging Phase 1 trial results for its drug candidate CX-2051, aimed at advanced colorectal cancer. The study indicated that the drug was well-tolerated and showed significant anti-tumor activity in patients, with 18 out of 23 participants able to be evaluated. The company highlights the drug's potential to address unmet medical needs in this challenging treatment area.
Source: YAHOO